Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01892345 · ClinicalTrials.gov registry record · Phase 3
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 143
- Enrollment target
NCT01892345 is a Phase 3 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 143 participants.
The verdict
NCT01892345, a Phase 3 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 143 participants
- Enrollment target
Study Summary
The objectives of this time-to-event study were to assess the efficacy and safety of eculizumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4) antibody-positive.
Interventions
- DRUG Placebo
- DRUG Eculizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2014-04-11 |
| Est. Completion | 2018-07-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01892345
The ClinicalTrials.gov registry entry for NCT01892345 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01892345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01892345 about?
NCT01892345 is a clinical study titled "A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)". The objectives of this time-to-event study were to assess the efficacy and safety of eculizumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4) antibody-positive.
What is the current status of trial NCT01892345?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 143 participants. The study started on 2014-04-11. Estimated completion is 2018-07-17.
What interventions are being tested in trial NCT01892345?
The interventions under investigation include: Placebo (DRUG), Eculizumab (DRUG).
Who is sponsoring clinical trial NCT01892345?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.